Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
5.33
+0.35 (7.03%)
At close: Mar 6, 2026, 4:00 PM EST
5.30
-0.03 (-0.56%)
After-hours: Mar 6, 2026, 7:32 PM EST
Immuneering Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Immuneering stock have an average target of 17.2, with a low estimate of 10 and a high estimate of 30. The average target predicts an increase of 222.70% from the current stock price of 5.33.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 13, 2025.
Analyst Ratings
The average analyst rating for Immuneering stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $20 | Strong Buy | Maintains | $20 | +275.23% | Nov 13, 2025 |
| Leerink Partners | Leerink Partners | Buy Initiates $15 | Buy | Initiates | $15 | +181.43% | Oct 31, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +106.38% | Sep 30, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $13 → $20 | Strong Buy | Maintains | $13 → $20 | +275.23% | Sep 26, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $21 → $30 | Buy | Maintains | $21 → $30 | +462.85% | Sep 25, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.45
from -2.04
EPS Next Year
-1.41
from -1.45
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.35 | -1.17 | ||||
| Avg | -1.45 | -1.41 | ||||
| Low | -1.53 | -1.54 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.